The global autotransfusion devices market size is predicted to reach USD 320.5 million by 2026, exhibiting a CAGR of 3.2% during the forecast period. The shortage of allogeneic blood and surge in invasive surgeries in developed as well as developing countries will boost the autotransfusion devices market trends in the forthcoming years. According to a survey conducted by World Health Organization (WHO) in 2016, the patient group over 60 years had the highest consumption of allogeneic blood, accounting for an estimated 79.0% of the total blood transfusion that took place in the developed regions. Moreover, the increasing number of surgical procedures and surge in critical injuries are factors expected to fuel demand for autotransfusion devices in the foreseeable future.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/autotransfusion-devices-market-101899
According to the report, published by Fortune Business Insights in a report, titled “Autotransfusion Devices Market Size, Share & Industry Analysis, By Product Type (Autotransfusion Systems and Consumables & Accessories) By Application (Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, Obstetrics & Gynecological Surgeries, and Others) By End User (Hospitals and Specialty Clinics & Others) and Regional Forecast, 2019-2026” the market size was valued at USD 249.2 million in 2018.
Some of the Major Companies in the Autotransfusion Devices Market are:
- Haemonetics Corporation
- LivaNova PLC
- Fresenius SE & Co. KGaA
- BD (Becton, Dickinson, and Company)
- Beijing Jingjing Medical Equipment Co., Ltd.
- Other Prominent Players
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/autotransfusion-devices-market-101899
Robust Healthcare Infrastructure to Boost Revenue in North America
North America generated a revenue of USD 125.8 million in 2018 and is projected to remain dominant in the autotransfusion devices market during the forecast period. The rising inclination towards autologous blood transfusion in major cardiovascular & orthopedic surgeries will support the growth of the autologous blood transfusion devices market in North America. The developed healthcare infrastructure will further contribute to the growth of the market in North America. In Europe, the rapidly increasing number of surgeries coupled with a strong emphasis on the adoption of intraoperative and postoperative cell salvage techniques are likely to offer substantial growth opportunities for the market.
Additionally, growing efficiency in blood transfusion devices in countries such as the UK, France, Germany, and others will further foster the growth of the market in Europe. According to a study conducted by Cochrane in 2010, the use of autotransfusion systems in orthopedic and cardiovascular surgical procedures showed an average saving of 0.7 units of blood per patient. These factors together are expected to aid the expansion of the market in Europe.
Table of Content:
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Key Industry Developments- Partnerships, Mergers and Acquisitions
- Number of Cardiovascular Procedures for Key Countries, 2018
- Number of Orthopedic Procedures for Key Countries, 2018
- Number of Obstetrics & Gynecological Procedures for Key Countries, 2018
More Trending Topics from Fortune Business Insights: